Addressing Disparities in Stem Cell Transplant for Myeloma

Although most patients with cancer receive treatment in community settings, patients with multiple myeloma may benefit from evaluation at a tertiary care center to assess eligibility for specialized treatment, including autologous stem cell transplant (ASCT). However, disparities in access to transplant persist, highlighting the need for strategies that help patients overcome barriers to specialized care.

In this interview with Targeted Oncology, Ashley Rosko, MD, of The Ohio State University Comprehensive Cancer Center, discusses research examining disparities in ASCT receipt among patients with newly diagnosed multiple myeloma and opportunities to improve access to care. ASCT remains a standard treatment approach for eligible patients with newly diagnosed multiple myeloma, yet certain populations are less likely to receive a transplant.

In an analysis of nearly 2000 patients, investigators identified several factors associated with a lower likelihood of receiving ASCT, including older age, Black or African American race, and residence in areas with lower socioeconomic status. These findings reflect previously reported disparities and underscore the multifactorial challenges that can prevent patients from accessing specialized treatment.

Dr Rosko discusses the importance of identifying populations at risk of underutilizing transplant and exploring interventions to reduce barriers to care. She highlights the role of collaboration between community oncology practices and tertiary care centers in helping patients access appropriate evaluation and treatment while remaining connected to their local communities.

For community oncologists, recognizing disparities in transplant referral and receipt is an important step toward improving equitable access to multiple myeloma care. Understanding which patients may face additional barriers can help inform referral practices and support efforts to ensure that eligible patients have the opportunity to undergo transplant evaluation.